Nature Communications (Jul 2018)
Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission
- Shinya Tasaki,
- Katsuya Suzuki,
- Yoshiaki Kassai,
- Masaru Takeshita,
- Atsuko Murota,
- Yasushi Kondo,
- Tatsuya Ando,
- Yusuke Nakayama,
- Yuumi Okuzono,
- Maiko Takiguchi,
- Rina Kurisu,
- Takahiro Miyazaki,
- Keiko Yoshimoto,
- Hidekata Yasuoka,
- Kunihiro Yamaoka,
- Rimpei Morita,
- Akihiko Yoshimura,
- Hiroyoshi Toyoshiba,
- Tsutomu Takeuchi
Affiliations
- Shinya Tasaki
- Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Katsuya Suzuki
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
- Yoshiaki Kassai
- Immunology Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Masaru Takeshita
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
- Atsuko Murota
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
- Yasushi Kondo
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
- Tatsuya Ando
- Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Yusuke Nakayama
- Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Yuumi Okuzono
- Immunology Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Maiko Takiguchi
- Immunology Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Rina Kurisu
- Immunology Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Takahiro Miyazaki
- Immunology Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Keiko Yoshimoto
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
- Hidekata Yasuoka
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
- Kunihiro Yamaoka
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
- Rimpei Morita
- Department of Microbiology and Immunology, Keio University School of Medicine
- Akihiko Yoshimura
- Department of Microbiology and Immunology, Keio University School of Medicine
- Hiroyoshi Toyoshiba
- Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Tsutomu Takeuchi
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-018-05044-4
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 12
Abstract
Little information is available on molecular changes in response to treatment of rheumatoid arthritis (RA). Here the authors report a multi-omics study collecting patients' transcriptome, proteome, and immunophenotype data to help understand the impact of drug treatments on RA molecular phenotypes.
